advertisement
Abstract #8848 Published in IGR 5-1
Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost
Williams RDAdvances in Therapy 2002; 19: 275-81
This open-label, monocular, two-phase trial was conducted to determine whether bimatoprost is effective in patients with open-angle glaucoma or ocular hypertension not responsive to latanoprost. After a four-week washout of any ocular hypotensive agents, patients with IOP between 22 and 34 mmHg (n = 51) instilled latanoprost in one eye and were evaluated at weeks 4 and 8 (phase 1). Patients with an IOP reduction no more than 3 mmHg at both visits were considered nonresponders to latanoprost and were switched to bimatoprost for eight weeks (n = 21) (phase 2). In the treated eyes, the mean reduction in IOP from baseline after four weeks of each medication was 2.3 mmHg with latanoprost (p = 0.012) and 6.1 mmHg with bimatoprost (p < 0.001). After eight weeks, respective IOP reductions were 1.9 (p = 0.027) and 5.4 mmHg (p < 0.001). After the switch from latanoprost, eight weeks of bimatoprost provided an additional mean IOP reduction of 3.5 mmHg (p < .001).
Dr. R.D. Williams, Taustine Eye Center, Louisville, KY 40217, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
